Why the study?
Does warfarin therapy reduce thromboembolism and ischemic stroke in patients with nonvalvular atrial fibrillation in a real-world managed care setting?
Population
12,539 subjects with nonvalvular atrial fibrillation within a managed care organization, mean age 78.0 +/…
Comparison
Warfarin therapy (newly initiating) vs No warfarin therapy
Design
Cohort
Follow-up
maximum 720-day
Authors
Loading...
Warfarin was associated with lower thromboembolism risk in real-world NVAF without excess hemorrhage; leaves open whether benefits hold versus contemporary NOACs.
Does warfarin therapy reduce thromboembolism and ischemic stroke in patients with nonvalvular atrial fibrillation in a real-world managed care setting?
In a real-world managed care setting, warfarin therapy for nonvalvular atrial fibrillation significantly reduced thromboembolism and ischemic stroke without increasing hemorrhage risk, though it remains underused.
Darkow et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: